Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy

被引：0
|
作者：
Markus Kieler
Matthias Unseld
Johann Wojta
Alexandra Kaider
Daniela Bianconi
Svitlana Demyanets
Gerald W. Prager
机构：
[1] Medical University Vienna,Division of Oncology, Department of Medicine I, Comprehensive Cancer Center
[2] Medical University Vienna,Division of Cardiology, Department of Internal Medicine II
[3] Medical University of Vienna,Center for Medical Statistics, Informatics and Intelligent Systems
[4] Medical University of Vienna,Department of Laboratory Medicine
来源：
Medical Oncology | 2019年 / 36卷
关键词：
IL-33; sST2; Cytokines; Pancreatic ductal adenocarcinoma; Chronic inflammation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Interleukin-33 (IL-33) and its “decoy” receptor soluble ST2 (sST2) are involved in the development of chronic inflammation and cancer. We explored IL-33 and sST2 as a potential prognostic marker in patients with metastatic and locally advanced pancreatic ductal adenocarcinoma (PDAC). IL-33 and sST2 plasma levels were assessed in 20 patients with advanced PDAC before start of systemic chemotherapy and were analyzed in relation to clinical outcome. Kaplan Meier and multivariable Cox proportional hazards model analysis revealed a significant association between sST2 plasma levels and survival (HR 2.10, 95% CI 1.33–3.41, p = 0.002) and link high sST2 plasma levels to inferior survival in patients with advanced PDAC undergoing chemotherapy.
引用
收藏
相关论文
共 50 条
  • [1] Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
    Kieler, Markus
    Unseld, Matthias
    Wojta, Johann
    Kaider, Alexandra
    Bianconi, Daniela
    Demyanets, Svitlana
    Prager, Gerald W.
    MEDICAL ONCOLOGY, 2019, 36 (01)
  • [2] Plasma levels of interleukin-33 (IL-33) and soluble suppression of tumorigenicity 2 (sST2) as a potential predictive biomarker in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systemic chemotherapy (sCTX)
    Kieler, M.
    Unseld, M.
    Demyanets, S.
    Bianconi, D.
    Prager, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
    Iannazzo, Francesco
    Pellicano, Chiara
    Colalillo, Amalia
    Ramaccini, Cesarina
    Romaniello, Antonella
    Gigante, Antonietta
    Rosato, Edoardo
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (03) : 897 - 903
  • [4] Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
    Francesco Iannazzo
    Chiara Pellicano
    Amalia Colalillo
    Cesarina Ramaccini
    Antonella Romaniello
    Antonietta Gigante
    Edoardo Rosato
    Clinical and Experimental Medicine, 2023, 23 : 897 - 903
  • [5] Serum interleukin-33 and soluble suppression of tumorigenicity 2 in pediatric leukemia with febrile neutropenia
    Merve Cansu Polat
    Çiğdem Sönmez
    Neşe Yarali
    Namık Yaşar Özbek
    European Journal of Pediatrics, 2024, 183 : 2155 - 2162
  • [6] Serum interleukin-33 and soluble suppression of tumorigenicity 2 in pediatric leukemia with febrile neutropenia
    Polat, Merve Cansu
    Sonmez, Cigdem
    Yarali, Nese
    Ozbek, Namik Yasar
    EUROPEAN JOURNAL OF PEDIATRICS, 2024, 183 (05) : 2155 - 2162
  • [7] Interleukin-33 and its receptor soluble suppression of tumorigenicity 2 in the diagnosis of gestational diabetes mellitus
    Fan, Wei
    Kang, Wei
    Li, Tao
    Luo, Dandan
    Huang, Lei
    Yang, Yimei
    Sun, Yu
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (12)
  • [8] Interleukin-33/ Suppression of Tumorigenicity 2 in Renal Fibrosis: Emerging Roles in Prognosis and Treatment
    Tan, Xiao-Yang
    Jing, Hao-Yue
    Ma, Yue-Rong
    FRONTIERS IN PHYSIOLOGY, 2022, 12
  • [9] Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis
    Yuan, L.
    Yao, L.
    Zhao, L.
    Xia, L.
    Shen, H.
    Lu, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (03) : 428 - 432
  • [10] Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy
    Lindgaard, Sidsel C.
    Maag, Emil
    Sztupinszki, Zsofia
    Chen, Inna M.
    Johansen, Astrid Z.
    Jensen, Benny, V
    Bojesen, Stig E.
    Nielsen, Dorte L.
    Szallasi, Zoltan
    Johansen, Julia S.
    CANCERS, 2022, 14 (13)
12345